You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Silicon Valley venture capital firm Andreessen Horowitz led the round, joined by 8VC, SV Angel, Allen & Co, and several other undisclosed private investors.
The firm said it will use the funds for general corporate purposes, which may include investment and acquisitions, working capital, and debt repayment.
The companies collaborated in Wuhan during the COVID-19 outbreak, using Darui's pathogenic microorganism detection kits on Genetron's next-generation sequencer.
The approval is based on results of the PROfound trial, which included men with mutations in BRCA1/2 or ATM, and 12 other genes associated with the HRR pathway.
The deal includes integrating an online ordering process for Ambry's genetic tests into Volpara's Aspen Breast software for medical practice management.
The partners aim to develop unbiased omics-based methods for identifying cases of PTSD, which may increase in the wake of the COVID-19 pandemic.
French startup SeqOne has adapted its sequencing data-analysis platform to support a new method for high-throughput processing of coronavirus tests in its home country.
A handful of recently published trials suggest that use of the pneumonia panel could lead to more targeted therapy delivered more quickly than standard methods.
The two organizations announced a partnership earlier this year to manufacture and process Curative's oral fluid-based SARS-CoV-2 test.
The DeepChek-HIV assays are designed for settings running either Sanger sequencing or next-generation sequencing workflows, according to the company.
The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.
The listing enables assay developers and testing labs in the US to access the instrument for COVID-19 testing, the firm said.
The firm also received the CE mark for the test, which uses a reformulated buffer and takes less time to process than a test requiring an RNA extraction step.
The new funds will be used, in part, to support ChromaCode's expansion into resource-limited communities in low- to middle-income nations.
The FDA granted Emergency Use Authorization for Everlywell's at-home nasal swab collection kit, which can be used with Fulgent and Assurance's tests.
The acquisition will round out BD's molecular portfolio and be complementary to the firm's Veritor immunoassay system, according to executives.
Investigators are building upon an initial case study that allowed them to assess how well ctDNA captured a cancer's full genomic heterogeneity compared to tissue biopsies.
The PCR-based test works with upper and lower respiratory specimens, including nasal swabs and sputum, and can be performed by high complexity labs.
The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.
The Cedars-Sinai Medical Center SARS-CoV-2 RT-PCR assay uses the A*Star Fortitude Kit 2.0 for the detection of SAR-CoV-2 specific RNA in nasopharyngeal swab samples.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.